InfuSystem : Investor Presentation

Helping People Live Longer and

Healthier Lives

Investor Presentation

June 12, 2024 l (NYSE American: INFU)

Forward-Looking Statements / Non-GAAP Measures

Forward-Looking Statements

Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, our share repurchase program and capital allocation strategy, business plans, strategic partnerships, growth initiatives, objectives and prospects, future operating or financial performance, guidance and expected new business relationships and the terms thereof (including estimated potential revenue under new or existing contracts). The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "goal," "expect," "strategy," "future," "likely," variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward-looking statements are subject to factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, our ability to successfully execute on our growth initiatives and strategic partnerships, our ability to enter into definitive agreements for the new business relationships on expected terms or at all, our ability to generate estimated potential revenue amounts under new or existing contracts, our dependence on estimates of collectible revenue, potential litigation, changes in third-party reimbursement processes, changes in law, global financial conditions and recessionary risks, rising inflation and interest rates, supply chain disruptions, systemic pressures in the banking sector, including disruptions to credit markets, the Company's ability to remediate its previously disclosed material weakness in internal control over financial reporting, contributions from acquired businesses or new business lines, products or services and other risk factors disclosed in the Company's most recent annual report on Form 10-K and, to the extent applicable, quarterly reports on Form 10-Q. Our strategic partnerships are subject to similar factors, risks and uncertainties. All forward-looking statements made in this presentation speak only as of the date hereof. InfuSystem does not undertake any obligation to update any forward-looking statements to reflect future events or circumstances, except as required by law.

Non-GAAP Measures

This presentation contains information prepared in conformity with GAAP as well as non-GAAP financial information. The Company believes that the non- GAAP financial measures presented in this presentation provide useful information to the Company's management, investors and other interested parties about the Company's operating performance because they allow them to understand and compare the Company's operating results during the current periods to the prior year periods in a more consistent manner. This non-GAAP information should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP, and similarly titled non-GAAP measures may be calculated differently by other companies. The Company calculates those non-GAAP measures by adjusting for nonrecurring or non-core items that are not part of the normal course of business and that the Company's management does not believe will have similar comparable year-over-year items. A reconciliation of those measures to the most directly comparable GAAP measures is provided in Appendix A of this presentation.

2

Investment Highlights

38-Year History | Long-Term Blue Chip Customer Base

In Millions

Net Revenues	5	Five Consecutive Years of Record Revenue
	•	Revenue CAGR: 12%
	•	Adjusted EBITDA CAGR: 5%

2023 Adjusted EBITDA: $22.4M

Business Generates Substantial Annual Cash Flow

• $11.2M - 2023 Cash Flow Provided by Operations
  Solid Balance Sheet to Support Growth
• Net Leverage Ratio: 1.32x
• Debt/Equity Ratio: 1.01x

Medical Equipment Assets: ~$100M

NOLs: ~$26.6M

*Data as of March 31, 2024, unless otherwise noted

3

Business Highlights

A leading provider of medical equipment and

patient services powered by a 100K+ device fleet in the U.S. and Canada

Participating in-network

provider in more than 800

health insurance networks covering over 96% of the U.S. population, serving over 2,450 sites of care

*Source: Newsweek, World's Best Hospitals 2024

Nearly four decades of experience, built on existing Oncology therapy model and now rapidly expanding into multiple therapies

	Seven major
Serving nearly	service areas in
the U.S. and
5,000 customer
Canada with
locations
more than 500
	employees

National scale,

serving 18 out of

20 top-ranked hospital systems nationwide*

4

Providing Solutions To Manage the Device Throughout the Treatment Cycle

Device-Agnostic Services Platform That Improves Health Care Processes and Outcomes

Manufacturer	Provider
•	Product distribution	•	Equipment on demand
•	TRUSTED device care	•	Device agnostic
•	Preferred service center	• Lower admin costs - SMART
•	Recall remediation

Payer	SOLUTIONS Patient
• Lower cost of care -	•	SAFE quality equipment
SMART	•	Home treatment
• Improve patient outcomes	•	Last-mile solution
• Contracts covering over 96%	•	24-hour patient support
of the U.S. population	•	Patient satisfaction surveys

5

Patient Services

• Oncology • Pain Management
• • Wound Care

Device Solutions

• • Biomedical Services • Consumables
• Inventory Management • Sales, Rentals & Leasing

$76.5M (61%)

Patient Services

Facilitating outpatient care for patients requiring durable medical equipment

Total 2023

Revenue:

$125.8 Million

SALES BY SEGMENT

$49.3M (39%)

Device Solutions

Providing equipment, products and services to hospitals, clinics and home infusion providers

6

Competitive Advantages

• Significant Barriers to Entry in Patient Services
• Service-BasedCompetitive Advantages in Device Solutions

Patient Services

• 800+ national payer contracts covering over 96% of U.S. population
• Focused and scalable revenue cycle management team
• 24/7 clinical hotline
• Device agnostic

Device Solutions

• White Glove Concierge approach
• 7 facilities serving U.S. and Canada
• More than 200 biomedical technicians
• Extensive repair capabilities and expertise
• ISO 9001/13485 certified

7

Patient Services

Unique High-Service Platform, Third-Party Payer Model INFU Is Paid by the Patient's Insurance Provider

Device

Logistics

Device Repair & Maintenance

"The patient is at

the center of

everything we do."

Clinical Support/

Case Management

Revenue Cycle Management

Oncology (Core Business) Is Profitable and Stable Growth Opportunities Are Pain Management and Wound Care

8

Device Solutions

Traditional Medical Distribution, Direct Payer Model

INFU Is Paid Directly by the Hospital/Clinic/Home Care Provider

Sales, Rentals	Inventory
& Leasing	& Tracking

Medical Device

Trusted Device & Service

Provider

Device Repair &	Consumable
Maintenance	Sales

• Device Solutions (Core Business) Is Stable and Growing
• • Growth Opportunity Is Biomedical Services

9

Managing the Device Throughout the Treatment Cycle

Connecting and Enhancing Processes for Key Stakeholders To Solve Complex Problems

	Manufacturer		Provider
•	Distribution	•	Devices on demand
•	Device support	•	White Glove services
		• Third-party payer billing

SOLUTIONS

	Payer		Patient
•	Improved outcomes	•	Access to advanced
•	Lower costs		devices and products
		•	24/7 patient support

10